Related Experiment Video
Updated: May 31, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
The dawn of a revolution in personalized lung cancer prevention
1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, NE, Atlanta, GA 30322, USA. fkhuri@emory.edu
Abstract:
Lung cancer prevention and early detection, which have fallen on hard times for more than the past 20 years, seem to have turned a corner toward better times ahead. Exciting new results of randomized controlled trials that targeted the arachidonic acid pathway, including a celecoxib trial reported by Mao and colleagues in this issue of the journal (beginning on page 984) and a trial of the prostacyclin analog iloprost, complement recently reported 20%-30% lung cancer mortality reductions, either with aspirin in targeting the arachidonic acid pathway or with computed tomography screening. The new results show encouraging activity personalized to former smokers and/or people expressing predictive biomarkers. These trials and technological advances in molecular profiling and imaging herald substantial clinical advances on the horizon of this field.
Insights
Lung cancer prevention and early detection show promise with new targeted therapies and screening methods. Research highlights aspirin, computed tomography screening, and personalized approaches for former smokers and those with biomarkers.
Area of Science:
- Oncology
- Preventive Medicine
- Pharmacology
Background:
- Lung cancer prevention and early detection efforts have faced challenges over the past two decades.
- Recent advancements suggest a potential turning point with promising new research findings.
Purpose of the Study:
- To review recent randomized controlled trials and technological advances in lung cancer prevention and early detection.
- To highlight the potential of targeted therapies and personalized approaches.
Main Methods:
- Review of randomized controlled trials targeting the arachidonic acid pathway (celecoxib, iloprost, aspirin).
- Inclusion of data on computed tomography screening.
- Consideration of personalized strategies for specific patient groups and biomarkers.
Main Results:
- Randomized controlled trials show encouraging activity in targeting the arachidonic acid pathway.
- Aspirin and computed tomography screening have demonstrated 20%-30% lung cancer mortality reductions.
- Personalized approaches show promise for former smokers and individuals with predictive biomarkers.
Conclusions:
- New therapeutic targets and screening technologies signal substantial clinical progress in lung cancer.
- Personalized medicine and targeted pathways represent the future of lung cancer prevention and early detection.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...